pyrrocaine 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | PK/Tox | Related Drugs | BioActivity |

Stem definitionDrug idCAS RN
local anaesthetics 3512 2210-77-7

Description:

MoleculeDescription

Molfile Inchi Smiles

Synonyms:

  • pyrrocaine monohydrochloride
  • pyrrocaine hydrochloride
  • pyrrocaine
  • endocaine
  • pirothesin
  • Molecular weight: 232.33
  • Formula: C14H20N2O
  • CLOGP: 1.64
  • LIPINSKI: 0
  • HAC: 3
  • HDO: 1
  • TPSA: 32.34
  • ALOGS: -2.14
  • ROTB: 3

Drug dosage:

None

ADMET properties:

None

Predicted pharmacokinetic/toxicological properties (PK-AZ):

PropertyDescriptionValueUnitConfidenceSimilarity
azlogd74 LogD at pH 7.4 1.189 Moderate 0.71
caco2-efflux Caco-2 efflux ratio (BA/AB) 0.469 Moderate 0.71
caco2-intrinsic-papp Caco-2 intrinsic apparent permeability 44.361 10^-6 cm/s Moderate 0.71
dh-clint Dog hepatocyte intrinsic clearance 16.749 uL/min/10^6 cells Moderate 0.71
dppb Dog plasma protein binding (% unbound) 75.210 % Moderate 0.71
fcs-ppb Fetal calf serum protein binding (% unbound) 84.480 % Moderate 0.71
herg hERG pIC50 4.430 pIC50 Moderate 0.71
hh-clint Human hepatocyte intrinsic clearance 1.556 uL/min/10^6 cells Moderate 0.71
hlm-clint Human liver microsomal intrinsic clearance 4.477 uL/min/mg protein Moderate 0.71
hppb Human plasma protein binding (% unbound) 76.140 % Moderate 0.71
kinase-safety-class ACVR2A,ACVR2B,AXL,BRAF,BTK,CAMK2B,CAMK2D,CDK5,CDK9,DDR1,DYRK1B,EGFR,EIF2AK3,EPHB4,ERBB2,GRK2,ITK,MAP3K21,MAP3K7,MAPK7,MAPKAPK2,MET,NTRK2,PDK2,PDK4,PIK3CB,PRKDC,SIK2,SIK3,STK33,TEK 31
kinase-selectivity-class AXL,BRAF,DDR1,ERBB2,GRK2,MAPK7,PDK4,SIK2 8
mdck-mdr1-efflux MDCK-MDR1 efflux ratio 0.348 Moderate 0.71
mh-clint Mouse hepatocyte intrinsic clearance 62.087 Moderate 0.71
mppb Mouse plasma protein binding (% unbound) 80.110 Moderate 0.71
nih-mdck-mdr1-efflux NIH MDCK-MDR1 efflux ratio 0.942 Moderate 0.71
pfas-class PFAS structural alert (1 = True, 0 = False) 0
pppb Pig plasma protein binding (% unbound) 84.210 % Moderate 0.71
rh-clint Rat hepatocyte intrinsic clearance 66.834 uL/min/10^6 cells Moderate 0.71
rh-fuinc Rat hepatocyte fraction unbound in incubation 93.950 % Moderate 0.71
rppb Rat plasma protein binding (% unbound) 82.050 % Moderate 0.71
solubility-dd Solubility at pH 7.4 in DMSO 944.061 uM Moderate 0.71

Approvals:

None

FDA Adverse Event Reporting System (Female)

None

FDA Adverse Event Reporting System (Male)

None

FDA Adverse Event Reporting System (Geriatric)

None

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

None

Drug Use | Suggest Off label Use Form| |View source of the data|

None




🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation levelDissociation constantType (acidic/basic)
pKa1 13.4 acidic
pKa2 7.92 Basic

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

None

External reference:

IDSource
D05665 KEGG_DRUG
2210-64-2 SECONDARY_CAS_RN
C0609331 UMLSCUI
CHEBI:134946 CHEBI
CHEMBL1895219 ChEMBL_ID
CHEMBL2104803 ChEMBL_ID
24361 PUBCHEM_CID
C022845 MESH_SUPPLEMENTAL_RECORD_UI
1363 INN_ID
9D47L94CPW UNII
9D47L94CPW INXIGHT DRUGS

Pharmaceutical products:

None